Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
---|---|---|---|---|---|---|---|---|
POLYOXYL 20 CETOSTEARYL ETHER | SPECIFIC TESTS/Average Polymer Length | USP36–NF31 | 2155 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 16 of Analysis: Change Result = [32 × A2/(A1 − 3)]/4 to: Result = [(32 × A2/A1) − 3]/4 |
POLYSORBATE 80 | SPECIFIC TESTS/Viscosity—Capillary Viscometer Methods <911> and Rotational Rheometer Methods <912> | USP36–NF31 | 2163 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1: Change and to: or |
POTASSIUM METAPHOSPHATE | SPECIFIC TESTS/Viscosity—Capillary Viscometer Methods <911> and Rotational Rheometer Methods <912> | USP36–NF31 | 2172 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1: Change and to: or |
SORBITAN MONOLAURATE | IDENTIFICATION/A. | USP36–NF31 | 2212 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Sample: Change 1 g of the residue obtained in the Assay for Fatty Acids to: Residue obtained in the Assay for Fatty Acids AND Line 2 of Acceptance criteria: Change 260–280 to: 260–280 on 1-g sample |
SORBITAN MONOOLEATE | IDENTIFICATION/A. | USP36–NF31 | 2213 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Sample: Change 1 g of the residue obtained in the Assay for Fatty Acids to: Residue obtained in the Assay for Fatty Acids AND Line 2 of Acceptance criteria: Change 192–204 to: 192–204 on 1-g sample |
SORBITAN MONOPALMITATE | IDENTIFICATION/A. | USP36–NF31 | 2213 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Sample: Change 1 g of the residue obtained in the Assay for Fatty Acids to: Residue obtained in the Assay for Fatty Acids AND Line 2 of Acceptance criteria: Change 210–225 to: 210–225 on 1-g sample |
SORBITAN MONOSTEARATE | IDENTIFICATION/A. | USP36–NF31 | 2214 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Sample: Change 1 g of the residue obtained in the Assay for Fatty Acids to: Residue obtained in the Assay for Fatty Acids AND Line 2 of Acceptance criteria: Change 200–215 to: 200–215 on 1-g sample |
SORBITAN SESQUIOLEATE | IDENTIFICATION/A. | USP36–NF31 | 2215 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Sample: Change 1 g of the residue obtained in the Assay for Fatty Acids to: Residue obtained in the Assay for Fatty Acids AND Line 2 of Acceptance criteria: Change 192–204 to: 192–204 on 1-g sample |
SORBITAN TRIOLEATE | IDENTIFICATION/A. | USP36–NF31 | 2216 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Sample: Change 1 g of the residue of oleic acid obtained in the Assay for Fatty Acids to: Residue obtained in the Assay for Fatty Acids AND Line 2 of Acceptance criteria: Change 192–204 to: 192–204 on 1-g sample |
STEAROYL POLYOXYLGLYCERIDES | IMPURITIES/Limit of Free Glycerol | USP36–NF31 | 2250 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 11 of Analysis: Change (VS − VB) to: (VB − VS) AND Line 12 of Analysis: Change VS = Titrant volume consumed by the Sample… Read More |
STEARYL ALCOHOL | SPECIFIC TESTS/Fats and Fixed Oils, Hydroxyl Value <401> | USP36–NF31 | 2252 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 14 of Analysis: Change [(VS − VB) × N × F]/W to: [(VB − VS) × N × Mr]/W AND Line 15 of Analysis: Change… Read More |
BUTABARBITAL SODIUM TABLETS | Identification, Infrared Absorption <197K> | USP36–NF31 | 2716 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 5 of Test specimen: Change Proceed as directed for Column Partition Chromatography under Chromatography <621>, packing the chromatographic tube as follows. to: Pack a chromatographic tube as follows. |
CAFFEINE CITRATE INJECTION | Assay | USP36–NF31 | 2732 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 3 of Chromatographic system: Change 150-cm column to: 15-cm column |
CAFFEINE CITRATE ORAL SOLUTION | Assay | USP36–NF31 | 2733 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 3 of Chromatographic system: Change 150-cm column to: 15-cm column |
CARISOPRODOL, ASPIRIN, AND CODEINE PHOSPHATE TABLETS | USP Reference standards <11> | USP36–NF31 | 2813 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 2 of USP Codeine N-Oxide RS: Change C18H21O4 to: C18H21NO4 |
CLAVULANATE POTASSIUM | IMPURITIES/Organic Impurities/Procedure 3: Limit of Aliphatic Amines | USP36–NF31 | 3022 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | In the definition list in Analysis: Change CU = nominal concentration of Clavulanate Potassium in the Standard solution to: CU = nominal concentration of Clavulanate Potassium in the Sample solution |
DROSPIRENONE | IMPURITIES/Organic Impurities/Procedure 2 | USP36–NF31 | 3349 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | In footnote b of Table 4: Change 5β,17β-Dihydroxy-6β,7β:15β,16β-dimethylene-17α-pregnan-21-carboxylic acid, γ-lactone. to: 5β,17-Dihydroxy-6β,7β:15β,16β-dimethylene-3-oxo-17α-pregnan-21-carboxylic acid, γ-lactone. |
ESOMEPRAZOLE MAGNESIUM | SPECIFIC TESTS/Color of Solution | USP36–NF31 | 3464 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Sample solution: Change 20 mg/mL of Esomeprazole Magnesium in methanol to: 20 mg/mL of Esomeprazole Magnesium in methanol, filtered |
ETHIODIZED OIL INJECTION | Viscosity—Capillary Viscometer Methods <911> and Rotational Rheometer Methods <912> | USP36–NF31 | 3505 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1: Change and to: or |
FERUMOXSIL ORAL SUSPENSION | Viscosity—Capillary Viscometer Methods <911> and Rotational Rheometer Methods <912> | USP36–NF31 | 3572 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1: Change and to: or |
MERCAPTOPURINE TABLETS | IMPURITIES/Organic Impurities/Procedure | USP36–NF31 | 4249 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 6 of Sample stock solution: Change Dilute with water to volume. to: Dilute with Solution A to volume. |
METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE TABLETS | PERFORMANCE TESTS/Dissolution <711>/Test 2/System suitability | USP36–NF31 | 4327 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Capacity factor: Change NMT 2 to: NLT 2 |
OCTOCRYLENE | Identification, Ultraviolet Absorption <197U> | USP36–NF31 | 4557 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 4: Change Absorptivities, calculated on the as-is basis, to: Absorptivity at 303 nm, calculated on the as-is basis, |
OXYMETAZOLINE HYDROCHLORIDE OPHTHALMIC SOLUTION | Identification | USP36–NF31 | 4652 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1: Change A volume of Ophthalmic Solution, equivalent to about 2.5 mg of oxymetazoline hydrochloride, responds to the Identification test under Oxymetazoline Hydrochloride Nasal Solution. to: Place a volume of Ophthalmic Solution, equivalent to about 2.5 mg of… Read More |
POLYVINYL ALCOHOL | SPECIFIC TESTS/Viscosity—Capillary Viscometer Methods <911>, Rotational Rheometer Methods <912>, and Rolling Ball Viscometer Method <913> | USP36–NF31 | 4830 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 2: Change and to: or |
QUININE SULFATE | IMPURITIES/Dihydroquinine Sulfate | USP36–NF31 | 4995 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 5 of Analysis: Change Result = (rU/rS) × 100 to: Result = rU/(rU + rS) × 100 |
RIFAMPIN, ISONIAZID, PYRAZINAMIDE, AND ETHAMBUTOL HYDROCHLORIDE TABLETS | Assay for rifampin, isoniazid, and pyrazinamide | USP36–NF31 | 5047 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 12 of Procedure: Change the Standard preparation and the Assay preparation, respectively. to: the Assay preparation and the Standard preparation, respectively. |
RIMEXOLONE OPHTHALMIC SUSPENSION | Viscosity—Capillary Viscometer Methods <911> and Rotational Rheometer Methods <912> | USP36–NF31 | 5053 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1: Change and to: or |
RIVASTIGMINE TARTRATE | CHEMICAL INFORMATION | USP36–NF31 | 5073 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1: Change 398.41 to: 400.42 |
SALICYLIC ACID | USP Reference standards <11> | USP36–NF31 | 5098 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 3 of USP Salicylic Acid Related Compound A RS: Change [CAS-99-96-7]. to: [99-96-7]. AND Line 3 of USP Salicylic Acid Related Compound B RS: Change C8H6O4 to: C8H6O5 |
TERAZOSIN CAPSULES | PERFORMANCE TESTS/Dissolution <711>/Test 1/Spectrometric conditions | USP36–NF31 | 5308 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Analytical wavelength: Change UV 245 nm to: UV 246 nm AND Line 3 of Cell length: Change 0.2 cm for Capsules labeled to contain 10 mg to: 0.5 cm for Capsules labeled to contain 10 mg |
COMPOUND UNDECYLENIC ACID OINTMENT | Assay for zinc undecylenate | USP36–NF31 | 5516 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 15 of Procedure: Change 431.94 is the molecular weight of zinc undecylenate; to: Mr is the molecular weight of zinc undecylenate, 431.94; AND Line 16 of Procedure: Change 65.39 is the atomic weight of zinc; to: Ar… Read More |
URSODIOL TABLETS | IMPURITIES/Organic Impurities/Procedure | USP36–NF31 | 5520 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 2 of Sample solution: Change Tablets, equivalent to about 25 mg of ursodiol, to: Tablets, equivalent to about 250 mg of ursodiol, |
BACLOFEN | ASSAY/Procedure/Chromatographic system | First Supplement to USP36–NF31 | 5951 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Column: Change 250-cm to: 25.0-cm |
ISOSORBIDE MONONITRATE EXTENDED-RELEASE TABLETS | IMPURITIES/Organic Impurities, Procedure 2 | First Supplement to USP36–NF31 | 5996 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 3: Change the section head Isosorbide mononitrate related compound A stock solution: to: Isosorbide mononitrate related compound A standard stock solution: AND Line 7: Change the section head Isosorbide dinitrate stock solution: to: Isosorbide… Read More |
LOPINAVIR AND RITONAVIR TABLETS | PERFORMANCE TESTS/Dissolution <711> | First Supplement to USP36–NF31 | 6005 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Tolerances: Change 80.0% to: 80% |
QUININE SULFATE TABLETS | ASSAY/Procedure | First Supplement to USP36–NF31 | 6046 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 4 of Analysis: Change dihydroquinone sulfate to: dihydroquinine sulfate |
BETHANECHOL CHLORIDE | IMPURITIES/Heavy Metals, Method 1 <231> | Second Supplement to USP36–NF31 | 6568 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Test preparation: Change Bethacholine Chloride to: Bethanechol Chloride |
FILGRASTIM | ASSAY/Potency | Second Supplement to USP36–NF31 | 6606 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 7 of Preparation of cells for analysis: Change Column 1 is filled with 50 L of Medium B. to: Column 1 is filled with 50 µL of Medium B. |
PANCURONIUM BROMIDE INJECTION | IMPURITIES/Organic Impurities | Second Supplement to USP36–NF31 | 6677 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Footnote a of Table 1: Change Piperidinium, 1-[(2,3,5,16,17)-17-acetyloxy-3-hydroxy-2-(1-piperidinyl)androstan-16-yl]-1-methyl bromide. to: Piperidinium, 1-[(2,3,5,16,17)-17-acetyloxy-3-hydroxy-2-(1-piperidinyl)androstan-16-yl]-1-methyl. |
POLYMYXIN B SULFATE | IMPURITIES/Organic Impurities | Second Supplement to USP36–NF31 | 6686 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 2: Change Buffer, Mobile phase, Diluent, Sensitivity solution, to: Buffer, Mobile phase, Diluent, Standard solution, Sensitivity solution, AND Line 1 of Samples in Analysis: Change Standard solution, Sample solution, and … Read More |
STINGING NETTLE | COMPOSITION/Content of Total Amino Acids | USP36–NF31 | 1604 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Reagent solution: Change Solution containing 1.00 g of ninhydrin, 1.50 g of hydrindantin, to: Solution containing 1.00 g of ninhydrin, 150 mg of hydrindantin, |
POWDERED STINGING NETTLE | COMPOSITION/Content of Total Amino Acids | USP36–NF31 | 1606 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Reagent solution: Change Solution containing 1.00 g of ninhydrin, 1.50 g of hydrindantin, to: Solution containing 1.00 g of ninhydrin, 150 mg of hydrindantin, |
POWDERED STINGING NETTLE EXTRACT | COMPOSITION/Content of Total Amino Acids | USP36–NF31 | 1608 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Reagent solution: Change Solution containing 1.00 g of ninhydrin, 1.50 g of hydrindantin, to: Solution containing 1.00 g of ninhydrin, 150 mg of hydrindantin, |
GLYCERYL DISTEARATE | ASSAY/Procedure/Chromatographic system | USP36–NF31 | 2029 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Column temperature: Change Column temperature: 40° to: Temperatures Detector: 40° Column: 40° |
SODIUM HYDROXIDE | ASSAY/Procedure | USP36–NF31 | 2203 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 11 of Analysis: Change = volume of Titrant consumed by the Sample to the first endpoint (mL) to: = volume of Titrant consumed by the Sample to the second endpoint (mL) |
AMOXICILLIN | IMPURITIES/Organic Impurities/Procedure | USP36–NF31 | 2477 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 2 of Acceptance criteria: Change [Note—The reporting limit is 0.03% of the amoxicillin peak from the Standard solution. ] to: [Note—The reporting limit is 0.03 times the amoxicillin peak from the Standard solution. ] |
BETAMETHASONE SODIUM PHOSPHATE | Identification/B. Thin-Layer Chromatographic Identification Test <201> | USP36–NF31 | 2645 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Test solution: Change 1 mg per mL. to: 1 mg per mL in methanol. |
CALCIUM CARBONATE | IMPURITIES | USP36–NF31 | 2747 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Acceptance criteria in Limit of Fluoride: Change 50 ppm to: NMT 50 ppm AND Line 1 of Acceptance criteria in Mercury, Method IIa <261>: Change 0.5 ppm to: NMT 0.5 ppm |
CEFDINIR CAPSULES | IMPURITIES/Organic Impurities/Table 2 | USP36–NF31 | 2850 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Row 16 of Column 1: Change Cefdinir impurity 2e to: Cefdinir impurity 2f AND Row 21 of Column 1: Change Cefdinir impurity 3e to: Cefdinir impurity 3f |